Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Gradual Introduction: Start with application 2-3 times per week for the initial 1-2 weeks, allowing your skin to adapt
That said, some of its secondary effects may indirectly support overall gut health for certain individuals
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
Glutathione (GSH) is a small tripeptide built from three amino acids, glutamic acid, cysteine, and glycine, joined by an unusual gamma-glutamyl bond
Can be improved with treatments including radio frequency and ultrasonic cavitation
While all GLP-1 drugs influence appetite and metabolism, only some (like semaglutide and tirzepatide) are FDA-approved specifically for weight management
